Archive \ Volume.14 2023 Issue 4

Epidemiological Trends of Central Nervous System Neoplasms in Saudi Arabia: A Retrospective Analysis Over Three Decades

Kholoud S. Almasoudi , Arwa F. Flemban , Saeed M. Kabrah , Samah A. Alharbi , Hanaa Alahmadi , Hanan M. Abd Elmoneim , Ruba O. Almaghrabi , Asim A. Khogeer , Abdullah K. Bahakim , Sanad M. Alharthi , Saad M. Alharthi , Saad F. Alqahtani

Abstract

This retrospective study comprehensively analyses the epidemiological trends of Central Nervous System (CNS) cancers in Saudi Arabia over three decades, from 1990 to 2019. Utilizing data from the Institute for Health Metrics and Evaluation (IHME) and the Saudi Cancer Registry, the study examines incidence, prevalence, and mortality rates, offering a detailed depiction of CNS cancer trends in the region. The findings reveal a significant increase in the incidence of CNS cancers, with rates increasing from 1.1 to 3.63 per 100,000 population. Despite this rise, the incidence in Saudi Arabia remains lower than in more developed regions, suggesting regional variations in risk factors and healthcare practices. The study observes a marked decline in mortality rates, from 25% in 1990 to below 10% in 2019, indicative of the effect of advancements in early detection, molecular diagnostics, and therapeutic interventions. Gender disparities were apparent, with males exhibiting higher incidence and mortality rates, aligning with global epidemiological patterns. The study also highlights demographic variability in CNS cancer incidence, with a prominent increase in adult populations, particularly those aged 55 and above. These findings underscore the need for targeted public health strategies and healthcare policies to address the rising incidence and improve patient outcomes. The study advocates for future research focusing on the etiology of CNS cancers, particularly in genetic and environmental factors, and calls for international collaboration in research to understand global variations in CNS cancer trends.


Downloads: 54
Views: 130

How to cite:
Vancouver
Almasoudi KS, Flemban AF, Kabrah SM, Alharbi SA, Alahmadi H, Elmoneim HMA, et al. Epidemiological Trends of Central Nervous System Neoplasms in Saudi Arabia: A Retrospective Analysis Over Three Decades. Arch Pharm Pract. 2023;14(4):138-48. https://doi.org/10.51847/fjFE2clfis
APA
Almasoudi, K. S., Flemban, A. F., Kabrah, S. M., Alharbi, S. A., Alahmadi, H., Elmoneim, H. M. A., Almaghrabi, R. O., Khogeer, A. A., Bahakim, A. K., Alharthi, S. M., et al. (2023). Epidemiological Trends of Central Nervous System Neoplasms in Saudi Arabia: A Retrospective Analysis Over Three Decades. Archives of Pharmacy Practice, 14(4), 138-148. https://doi.org/10.51847/fjFE2clfis

Download Citation
References
  1. Galea-Holhoș LB, Delcea C, Siserman CV, Ciocan V. Age Estimation of Human Remains Using the Dental System: A Review. Ann Dent Spec. 2023;11(3):15.
  2. Siserman C, Delcea C, Matei HV, Vică ML. Major affective distress in testing forensic paternity. Rom J Leg Med. 2019;27(3):292-6.
  3. Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71(5):381-406.
  4. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: A Cancer J Clin. 2021;71(1):7-33.
  5. Moin A, Rizvi SMD, Hussain T, Gowda DV, Subaiea GM, Elsayed MMA, et al. Current Status of Brain Tumor in the Kingdom of Saudi Arabia and Application of Nanobiotechnology for Its Treatment: A Comprehensive Review. Life (Basel). 2021;11(5):421.
  6. Mohammed AA, Hamdan AN, Homoud AS. Histopathological Profile of Brain Tumors: A 12-year Retrospective Study from Madinah, Saudi Arabia. Asian J Neurosurg. 2019;14(4):1106-11.
  7. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. Corrigendum to: CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol. 2022;24(7):1214.
  8. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
  9. Nicoară ND, Marian P, Petriș AO, Delcea C, Manole F. A Review of The Role of Cognitive-Behavioral Therapy on Anxiety Disorders of Children And Adolescents. Pharmacophore. 2023;14(4):35-9.
  10. Gherman C, Enache A, Delcea C. The multi-factorial determinism of forensic expertise regarding sentence interruption on medical grounds and decision. J Forensic Leg Med. 2019;61:45-55.
  11. Hossain MJ, Xiao W, Tayeb M, Khan S. Epidemiology and prognostic factors of pediatric brain tumor survival in the US: Evidence from four decades of population data. Cancer Epidemiol. 2021;72:101942.
  12. Arora RS, Alston RD, Eden TO, Estlin EJ, Moran A, Birch JM. Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro Oncol. 2009;11(4):403-13.
  13. Chen B, Chen C, Zhang Y, Xu J. Recent incidence trend of elderly patients with glioblastoma in the United States, 2000-2017. BMC Cancer. 2021;21(1):54.
  14. Vienne-Jumeau A, Tafani C, Ricard D. Environmental risk factors of primary brain tumors: A review. Rev Neurol (Paris). 2019;175(10):664-78.
  15. Rus M, Matei R, Sandu ML, Delcea C, Siserman C. Emotional distress and coping strategies of health care workers during COVID-19 pandemic. Rom J Leg Med. 2020;28:442-50.
  16. Delcea C, Siserman C. Validation and Standardization of the Questionnaire for Evaluation of Paraphilic Disorders. Rom J Leg Med. 2020;28(1):14-20.
  17. Kurdi M, Butt NS, Baeesa S, Alghamdi B, Maghrabi Y, Bardeesi A, et al. Epidemiological distribution of primary central nervous system tumors in the Western Province of Saudi Arabia: a local registry from neuroscience-affiliated centers. Epidemiol Health. 2021;43:e2021037.
  18. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A Summary. Neuro Oncol. 2021;23(8):1231-51.
  19. Papageorgiou GI, Razis ED. CNS Tumors in Adolescents and Young Adults: The Need for a Holistic Specialized Approach. JCO Oncol Pract. 2020;16(4):155-62.
  20. Radu CC, Delcea C, Plesa A, Rad D. Transforming perceptions of drug consumption among youth through a Cognitive-Social-Medico-Legal Educational Approach. Pharmacophore. 2023;14(4):50-6.
  21. Ostrom QT, Francis SS, Barnholtz-Sloan JS. Epidemiology of Brain and Other CNS Tumors. Curr Neurol Neurosci Rep. 2021;21(12):68.
  22. Pineros M, Sierra MS, Izarzugaza MI, Forman D. Descriptive epidemiology of brain and central nervous system cancers in Central and South America. Cancer Epidemiol. 2016;44 Suppl 1:S141-S9.
  23. Law M. Advanced imaging techniques in brain tumors. Cancer Imaging. 2009;9 Spec No A(Special issue A):S4-9.
  24. Miranda-Filho A, Piñeros M, Soerjomataram I, Deltour I, Bray F. Cancers of the brain and CNS: global patterns and trends in incidence. Neuro Oncol. 2017;19(2):270-80.
  25. Poon MTC, Brennan PM, Jin K, Sudlow CLM, Figueroa JD. Might changes in diagnostic practice explain increasing incidence of brain and central nervous system tumors? A population-based study in Wales (United Kingdom) and the United States. Neuro Oncol. 2021;23(6):979-89.
  26. Rigau V, Zouaoui S, Mathieu-Daudé H, Darlix A, Maran A, Trétarre B, et al. French brain tumor database: 5-year histological results on 25 756 cases. Brain Pathol. 2011;21(6):633-44.
  27. Georgakis MK, Kalogirou EI, Liaskas A, Karalexi MA, Papathoma P, Ladopoulou K, et al. Anthropometrics at birth and risk of a primary central nervous system tumor: A systematic review and meta-analysis. Eur J Cancer. 2017;75:117-31.
  28. Ostrom QT, Adel Fahmideh M, Cote DJ, Muskens IS, Schraw JM, Scheurer ME, et al. Risk factors for childhood and adult primary brain tumors. Neuro Oncol. 2019;21(11):1357-75.
  29. Zhang C, Ostrom QT, Hansen HM, Gonzalez-Maya J, Hu D, Ziv E, et al. European genetic ancestry associated with risk of childhood ependymoma. Neuro Oncol. 2020;22(11):1637-46.
  30. Zhang C, Ostrom QT, Semmes EC, Ramaswamy V, Hansen HM, Morimoto L, et al. Genetic predisposition to longer telomere length and risk of childhood, adolescent, and adult-onset ependymoma. Acta Neuropathol Commun. 2020;8(1):173.
  31. Dahlhaus A, Prengel P, Spector L, Pieper D. Birth weight and subsequent risk of childhood primary brain tumors: An updated meta-analysis. Pediatr Blood Cancer. 2017;64(5):e26299.
  32. Bailey HD, Rios P, Lacour B, Guerrini-Rousseau L, Bertozzi AI, Leblond P, et al. Factors related to pregnancy and birth and the risk of childhood brain tumors: The ESTELLE and ESCALE studies (SFCE, France). Int J Cancer. 2017;140(8):1757-69.
  33. Johnson KJ, Lee JM, Ahsan K, Padda H, Feng Q, Partap S, et al. Pediatric cancer risk in association with birth defects: A systematic review. PLoS One. 2017;12(7):e0181246.
  34. Lupo PJ, Schraw JM, Desrosiers TA, Nembhard WN, Langlois PH, Canfield MA, et al. Association Between Birth Defects and Cancer Risk Among Children and Adolescents in a Population-Based Assessment of 10 Million Live Births. JAMA Oncol. 2019;5(8):1150-8.
  35. Mili F, Lynch CF, Khoury MJ, Flanders WD, Edmonds LD. Risk of childhood cancer for infants with birth defects. II. A record-linkage study, Iowa, 1983-1989. Am J Epidemiol. 1993;137(6):639-44.
  36. Botto LD, Flood T, Little J, Fluchel MN, Krikov S, Feldkamp ML, et al. Cancer risk in children and adolescents with birth defects: a population-based cohort study. PLoS One. 2013;8(7):e69077.
  37. Janitz AE, Neas BR, Campbell JE, Pate AE, Stoner JA, Magzamen SL, et al. Childhood cancer in children with congenital anomalies in Oklahoma, 1997 to 2009. Birth Defects Res A Clin Mol Teratol. 2016;106(7):633-42.
  38. Bjørge T, Cnattingius S, Lie RT, Tretli S, Engeland A. Cancer risk in children with birth defects and their families: a population-based cohort study of 5.2 million children from Norway and Sweden. Cancer Epidemiol Biomarkers Prev. 2008;17(3):500-6.
  39. Fisher PG, Reynolds P, Von Behren J, Carmichael SL, Rasmussen SA, Shaw GM. Cancer in children with nonchromosomal birth defects. J Pediatr. 2012;160(6):978-83.
  40. Baan R, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, et al. Carcinogenicity of radiofrequency electromagnetic fields. Lancet Oncol. 2011;12(7):624-6.
  41. Turner MC, Benke G, Bowman JD, Figuerola J, Fleming S, Hours M, et al. Occupational exposure to extremely low-frequency magnetic fields and brain tumor risks in the INTEROCC study. Cancer Epidemiol Biomarkers Prev. 2014;23(9):1863-72.
  42. Carles C, Esquirol Y, Turuban M, Piel C, Migault L, Pouchieu C, et al. Residential proximity to power lines and risk of brain tumor in the general population. Environ Res. 2020;185:109473.
  43. Wrensch M, Lee M, Miike R, Newman B, Barger G, Davis R, et al. Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. Am J Epidemiol. 1997;145(7):581-93.
  44. Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il'yasova D, Kinnersley B, et al. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet. 2017;49(5):789-94.
  45. Mortality GBD, Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71.
  46. Saeidi Borojeni HR, Najafi F, Khosravi Shadmani F, Darabi Z, Darbandi M, Farhadi K, et al. Disability-Adjusted Life Years and Mortality Rate Attributed to Brain and Central Nervous System Cancer in the Middle East and North Africa Countries. Neuroepidemiology. 2021;55(6):447-59.
  47. Khan S, Kambris MEK, AlShamsi ET. Epidemiology of brain tumors in the United Arab Emirates: a National Registry Cross-sectional Study. BMC Neurol. 2020;20(1):301.
  48. Salimi A, Zali A, Seddighi AS, Seddighi A, Meshkat S, Hosseini M, et al. Descriptive Epidemiology of Brain and Central Nervous System Tumours: Results from Iran National Cancer Registry, 2010-2014. J Cancer Epidemiol. 2020;2020:3534641.
  49. Tamimi AF, Tamimi I, Abdelaziz M, Saleh Q, Obeidat F, Al-Husseini M, et al. Epidemiology of Malignant and Non-Malignant Primary Brain Tumors in Jordan. Neuroepidemiology. 2015;45(2):100-8.
  50. El Hage S, Kawtharani M, Nabha S, El Masri J, Saad M. Distribution of Primary Brain Tumor Subtypes in Lebanon: A Multicenter Eleven-Year Study of 695 Patients. Cureus. 2021;13(9):e17918.
  51. Almatroudi A. Brain Tumors in Saudi Arabia: An Observational and Descriptive Epidemiological Analysis. Healthcare (Basel). 2022;10(9):1796.
  52. He Z, Wong ST, Yam KY. Newly-Diagnosed, Histologically-Confirmed Central Nervous System Tumours in a Regional Hospital in Hong Kong: An Epidemiological Study of 21 years. J Korean Neurosurg Soc. 2020;63(1):119-35.
  53. Pouchieu C, Gruber A, Berteaud E, Menegon P, Monteil P, Huchet A, et al. Increasing incidence of central nervous system (CNS) tumors (2000-2012): findings from a population-based registry in Gironde (France). BMC Cancer. 2018;18(1):653.
  54. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.
  55. Nomura E, Ioka A, Tsukuma H. Trends in the incidence of primary intracranial tumors in Osaka, Japan. Jpn J Clin Oncol. 2011;41(2):291-4.
  56. Mortazavi SMJ, Mortazavi SAR, Paknahad M. Cancers of the Brain and CNS: Global Patterns and Trends in Incidence. J Biomed Phys Eng. 2018;8(1):151-2.
  57. Taha MS, Almsned FM, Hassen MA, Atean IM, Alwbari AM, Alharbi QK, et al. Demographic and histopathological patterns of neuro-epithelial brain tumors in Eastern Province of Saudi Arabia. Neurosciences (Riyadh). 2018;23(1):18-22.
  58. Global Burden of Disease Cancer C, Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, et al. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022;8(3):420-44.
  59. Coleman MP. Cancer survival: global surveillance will stimulate health policy and improve equity. Lancet. 2014;383(9916):564-73.
  60. Mohammadi E, Ghasemi E, Azadnajafabad S, Rezaei N, Saeedi Moghaddam S, Ebrahimi Meimand S, et al. A global, regional, and national survey on burden and Quality of Care Index (QCI) of brain and other central nervous system cancers; global burden of disease systematic analysis 1990-2017. PLoS One. 2021;16(2):e0247120.
  61. Allemani C, Coleman MP. Public health surveillance of cancer survival in the United States and worldwide: The contribution of the CONCORD programme. Cancer. 2017;123 Suppl 24(Suppl 24):4977-81.
  62. Pulumati A, Pulumati A, Dwarakanath BS, Verma A, Papineni RVL. Technological advancements in cancer diagnostics: Improvements and limitations. Cancer Rep (Hoboken). 2023;6(2):e1764.
  63. Salhab HA, Khachfe HH, Fares MY, Belkacemi Y, Hosseini H. Central nervous system cancers in the Middle East and North Africa (MENA) region: where does Lebanon stand. Chin Clin Oncol. 2020;9(3):36.
  64. Fan Y, Zhang X, Gao C, Jiang S, Wu H, Liu Z, et al. Burden and trends of brain and central nervous system cancer from 1990 to 2019 at the global, regional, and country levels. Arch Public Health. 2022;80(1):209.
  65. Trimble EL, Abrams JS, Meyer RM, Calvo F, Cazap E, Deye J, et al. Improving cancer outcomes through international collaboration in academic cancer treatment trials. J Clin Oncol. 2009;27(30):5109-14.

 

 

 


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.